Medulläres Schilddrüsenkarzinom

Schlüsselwörter

RET-Gen - Mutation - Tyrosinkinase-Inhibitoren - Molekularpathologie - Calcitonin

Key words

RET gene - mutation - tyrosine kinase inhibitors - molecular pathology - calcitonin

Publication History

Article published online:
03 August 2022

• Literatur

• 1 Randle RW, Balentine CJ, Leverson GE. et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery 2017; 161: 137-146 DOI: 10.1016/j.surg.2016.04.053.
• 2 Mathiesen JS, Kroustrup JP, Vestergaard P. et al. Survival and Long-Term Biochemical Cure in Medullary Thyroid Carcinoma in Denmark 1997–2014: A Nationwide Study. Thyroid 2019; 29: 368-377 DOI: 10.1089/thy.2018.0564.
• 3 Kim SH, Kim BS, Jung SL. et al. Ultrasonographic findings of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. Korean J Radiol 2009; 10: 101-105 DOI: 10.3348/kjr.2009.10.2.101.
• 4 Lee S, Shin JH, Han BK. et al. Medullary thyroid carcinoma: comparison with papillary thyroid carcinoma and application of current sonographic criteria. Am J Roentgenol 2010; 194: 1090-1094 DOI: 10.2214/ajr.09.3276.
• 5 Woliński K, Rewaj-Łosyk M, Ruchała M. Sonographic features of medullary thyroid carcinomas – a systematic review and meta-analysis. Endokrynol Pol 2014; 65: 314-318 DOI: 10.5603/ep.2014.0043.
• 6 Allelein S, Ehlers M, Morneau C. et al. Measurement of Basal Serum Calcitonin for the Diagnosis of Medullary Thyroid Cancer. Horm Metab Res 2018; 50: 23-28 DOI: 10.1055/s-0043-122237.
• 7 Frank-Raue K, Schott M, Raue F. [Recommendation for Calcitonin Screening in Nodular Goiter]. Dtsch Med Wochenschr 2018; 143: 1065-1069 DOI: 10.1055/a-0585-8097.
• 8 Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. The Journal of clinical endocrinology and metabolism 2010; 95: 2655-2663 DOI: 10.1210/jc.2009-2368.
• 9 Torresan F, Mian C, Cavedon E. et al. Cure and survival of sporadic medullary thyroid carcinoma following systematic preoperative calcitonin screening. Langenbeckʼs archives of surgery 2019; 404: 411-419 DOI: 10.1007/s00423-019-01764-3.
• 10 Machens A, Dralle H. Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. Eur J Endocrinol 2016; 175: 219-228 DOI: 10.1530/eje-16-0325.
• 11 Wells Jr SA, Asa SL, Dralle H. et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25: 567-610 DOI: 10.1089/thy.2014.0335.
• 12 Margraf RL, Crockett DK, Krautscheid PM. et al. Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Hum Mutat 2009; 30: 548-556 DOI: 10.1002/humu.20928.
• 13 ARUP Laboratories. Mutation Databases – Multiple Endocrine Neoplasia type 2 (MEN2) and RET. Im Internet (Stand: 14.10.2021): http://arup.utah.edu/database/MEN2 / MEN2_welcome.php
• 14 Ciampi R, Romei C, Ramone T. et al. Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing. iScience 2019; 20: 324-336 DOI: 10.1016/j.isci.2019.09.030.
• 15 Romei C, Ciampi R, Casella F. et al. RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. Oncotarget 2018; 9: 9875-9884 DOI: 10.18632/oncotarget.23986.
• 16 Raue F, Frank-Raue K. Long-Term Follow-up in Medullary Thyroid Carcinoma. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer 2015; 204: 207-225 DOI: 10.1007/978-3-319-22542-5_10.
• 17 Kwon H, Kim WG, Jeon MJ. et al. Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy. Endocrine 2016; 53: 174-181 DOI: 10.1007/s12020-015-0849-6.
• 18 Machens A, Hofmann C, Hauptmann S. et al. Locoregional recurrence and death from medullary thyroid carcinoma in a contemporaneous series: 5-year results. Eur J Endocrinol 2007; 157: 85-93 DOI: 10.1530/eje-07-0095.
• 19 Machens A, Lorenz K, Dralle H. Prediction of biochemical cure in patients with medullary thyroid cancer. Br J Surg 2020; 107: 695-704 DOI: 10.1002/bjs.11444.
• 20 Machens A, Dralle H. Benefit-risk balance of reoperation for persistent medullary thyroid cancer. Ann Surg 2013; 257: 751-757 DOI: 10.1097/SLA.0b013e31826bc239.
• 21 Schlumberger M, Bastholt L, Dralle H. et al. 2012 European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J 2012; 1: 5-14 DOI: 10.1159/000336977.
• 22 Elisei R, Schlumberger MJ, Müller SP. et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013; 31: 3639-3646 DOI: 10.1200/jco.2012.48.4659.
• 23 Wells Jr SA, Robinson BG, Gagel RF. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134-141 DOI: 10.1200/JCO.2011.35.5040.
• 24 Koehler VF, Berg E, Adam P. et al. Real world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer. Thyroid 2021; DOI: 10.1089/thy.2021.0091.
• 25 Subbiah V, Hu MI, Wirth LJ. et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol 2021; 9: 491-501 DOI: 10.1016/s2213-8587(21)00120-0.